FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Related Topics >> meningitis | Africa

Burkina Faso first to receive African meningitis vax

Free Newsletter

FierceVaccines is a weekly update on the vaccine industry, with a special focus on the innovations revolutionizing the development and production of vaccines. Join thousands of lab research professionals who get FierceVaccines via weekly email. Sign up today!


MenAfriVac, a meningitis A vaccine created by the Serum Institute of India, will be dispensed to Burkina Faso's 12 million residents starting Dec. 6. It's the first in the WHO's continent-wide vaccination program, a $550 million venture that should innoculate 450 million people against meningitis by 2015. Meningitis A infected more than 78,000 in sub-Saharan Africa's "meningitis belt" last year, causing 4,053 deaths.

The affordable vaccine costs approximately 50 U.S. cents per dose, much less than the $120 for similar vaccines.

"The impact of this vaccine will be truly enormous," said Jean-Marie Okwo-Bele, the WHO's director of vaccines, to Reuters. "This will affect the lives of 450 million people who are at risk of this disease in the African meningitis belt."

Meningitis A outbreaks tend to occur during Africa's dry season from January to March. In the past, polysaccharide vaccines were used, but they only protect those vaccinated for a year, and have been ineffective against meningitis outbreaks.

- see the Reuters article

Related Articles:
New meningitis vax arrives in Africa
New vaccine offers hope in fight against pneumonia, meningtis
Novartis' meningitis B vax passes test

Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceVaccines Email Newsletter:
Be the first to comment
More stories about meningitis   Africa  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

This question is for testing whether you are a human visitor and to prevent automated spam submissions.